China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SHE:000999)
China · Delayed Price · Currency is CNY 28.88
+0.17 (0.59%)
Feb 27, 2026, 3:04 PM CST
SHE:000999 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 31,629 | 26,466 | 23,837 | 17,411 | 14,825 |
Other Revenue | - | 1,151 | 901.47 | 667.99 | 719.33 |
| 31,629 | 27,617 | 24,739 | 18,079 | 15,544 | |
Revenue Growth (YoY) | 14.53% | 11.63% | 36.84% | 16.31% | 13.98% |
Cost of Revenue | - | 13,434 | 11,675 | 8,354 | 6,561 |
Gross Profit | 31,629 | 14,183 | 13,064 | 9,725 | 8,984 |
Selling, General & Admin | - | 8,878 | 8,489 | 6,135 | 5,992 |
Research & Development | - | 801.75 | 714.5 | 593.94 | 560.2 |
Other Operating Expenses | 26,781 | 229.73 | 262.72 | 207.05 | 204.39 |
Operating Expenses | 26,781 | 9,992 | 9,521 | 6,942 | 6,770 |
Operating Income | 4,848 | 4,191 | 3,543 | 2,784 | 2,214 |
Interest Expense | - | -80.04 | -80.78 | -21.23 | -14.18 |
Interest & Investment Income | - | 133.9 | 125.1 | 118.11 | 101.08 |
Currency Exchange Gain (Loss) | - | 5.48 | 2.5 | -56.25 | -12.89 |
Other Non Operating Income (Expenses) | 12.31 | -15.21 | -17.44 | -4.11 | -1.11 |
EBT Excluding Unusual Items | 4,860 | 4,235 | 3,572 | 2,820 | 2,287 |
Impairment of Goodwill | - | - | - | -65.51 | -44.24 |
Gain (Loss) on Sale of Investments | - | 68.2 | -28.63 | 2.58 | 5.04 |
Gain (Loss) on Sale of Assets | - | 31.43 | 0.81 | 2.28 | 0.85 |
Asset Writedown | - | -19.67 | -82.35 | -34.3 | -8.1 |
Other Unusual Items | - | 278.8 | 292.43 | 237.69 | 202.96 |
Pretax Income | 4,860 | 4,594 | 3,754 | 2,963 | 2,444 |
Income Tax Expense | 1,439 | 815.87 | 580.97 | 466.43 | 345.41 |
Earnings From Continuing Operations | 3,422 | 3,778 | 3,173 | 2,497 | 2,099 |
Minority Interest in Earnings | - | -409.85 | -320.55 | -48.21 | -43.49 |
Net Income | 3,422 | 3,368 | 2,853 | 2,449 | 2,055 |
Net Income to Common | 3,422 | 3,368 | 2,853 | 2,449 | 2,055 |
Net Income Growth | 1.60% | 18.05% | 16.50% | 19.16% | 28.65% |
Shares Outstanding (Basic) | 1,661 | 1,665 | 1,656 | 1,669 | 1,654 |
Shares Outstanding (Diluted) | 1,661 | 1,665 | 1,663 | 1,669 | 1,654 |
Shares Change (YoY) | -0.22% | 0.10% | -0.33% | 0.90% | -0.15% |
EPS (Basic) | 2.06 | 2.02 | 1.72 | 1.47 | 1.24 |
EPS (Diluted) | 2.06 | 2.02 | 1.72 | 1.47 | 1.24 |
EPS Growth | 1.82% | 17.94% | 16.89% | 18.10% | 28.83% |
Free Cash Flow | - | 3,612 | 3,335 | 2,055 | 1,012 |
Free Cash Flow Per Share | - | 2.17 | 2.00 | 1.23 | 0.61 |
Dividend Per Share | - | 1.015 | 0.887 | 0.592 | 0.505 |
Dividend Growth | - | 14.41% | 49.99% | 17.26% | 70.53% |
Gross Margin | 100.00% | 51.36% | 52.81% | 53.79% | 57.79% |
Operating Margin | 15.33% | 15.17% | 14.32% | 15.40% | 14.24% |
Profit Margin | 10.82% | 12.20% | 11.53% | 13.54% | 13.22% |
Free Cash Flow Margin | - | 13.08% | 13.48% | 11.37% | 6.51% |
EBITDA | 5,486 | 4,829 | 4,228 | 3,251 | 2,643 |
EBITDA Margin | 17.34% | 17.48% | 17.09% | 17.98% | 17.00% |
D&A For EBITDA | 638.08 | 638.08 | 685.71 | 467.17 | 429.17 |
EBIT | 4,848 | 4,191 | 3,543 | 2,784 | 2,214 |
EBIT Margin | 15.33% | 15.17% | 14.32% | 15.40% | 14.24% |
Effective Tax Rate | 29.60% | 17.76% | 15.47% | 15.74% | 14.13% |
Revenue as Reported | - | - | - | 18,079 | 15,544 |
Advertising Expenses | - | 754.25 | 660.33 | 543.92 | 578.72 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.